GlassScriptPhysician profile
Joshua A Motes
NPI 1619105277
$8,098.12
in general payments reported to CMS, 2019-2025
49 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $874 · 2021: $1,206 · 2022: $777 · 2023: $1,413 · 2024: $1,546 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,910.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,456.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,238.57 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $917.90 | 2022-2025 | |
| Pfizer INC. | $730.34 | 2019-2025 | |
| Lilly USA, LLC | $332.00 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $306.54 | 2019-2025 | Ozempic, Saxenda, Wegovy |
| Biohaven Pharmaceuticals, INC. | $267.90 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.97 | 2024-2025 | Caplyta |
| Antares Pharma, INC. | $203.32 | 2022-2025 | Xyosted |
| Amarin Pharma, INC. | $198.47 | 2020-2021 | |
| Axsome Therapeutics, INC. | $185.98 | 2025 | Auvelity |
| Amgen INC. | $166.24 | 2021-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $164.46 | 2020-2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.28 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $163.58 | 2019-2023 | Proquad, Rotateq, Vaxneuvance |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Motes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.